Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through PIK3IP1-PI3K/AKT Axis in Acute Myeloid Leukemia

被引：0
|
作者：
Yang, Chan [1 ]
Zi, Jie [1 ]
Song, Chunhua [2 ]
Ge, Zheng [1 ]
机构：
[1] Southeast Univ, Inst Hematol Southeast Univ, Sch Med, Zhongda Hosp, Nanjing, Peoples R China
[2] Ohio State Univ, Coll Med, Hershey, PA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152796
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3345
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia
    Yang, Chan
    Gu, Yan
    Ge, Zheng
    Song, Chunhua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [2] BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia
    Yao, Ming-Yue
    Wang, Ya-Fang
    Zhao, Yu
    Ling, Li-Jun
    He, Ye
    Wen, Jie
    Zheng, Ming-Yue
    Jiang, Hua-Liang
    Xie, Cheng-Ying
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (08): : 3829 - 3842
  • [3] UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activation
    Wang, Li
    Zhao, Shuqin
    Wang, Yongling
    Liu, Jianying
    Wang, Xiaoli
    BMC CANCER, 2024, 24 (01)
  • [4] MicroRNA-448 inhibits the regeneration of spinal cord injury through PI3K/AKT/Bcl-2 axis
    Lv, C. -L.
    Zhang, T.
    Yan, T. -Z.
    Yi, G. -K.
    Gao, K.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (07) : 2719 - 2726
  • [5] Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia
    Hurrish, Katie Hege
    Qiao, Xinan
    Li, Xinyu
    Su, Yongwei
    Carter, Jenna
    Ma, Jun
    Kalpage, Hasini A.
    Huttemann, Maik
    Edwards, Holly
    Wang, Guan
    Kim, Seongho
    Dombkowski, Alan
    Bao, Xun
    Li, Jing
    Taub, Jeffrey W.
    Ge, Yubin
    BIOCHEMICAL PHARMACOLOGY, 2022, 205
  • [6] EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway
    Wan, Dongdong
    Han, Xiuxin
    Zhang, Chao
    Zhang, Yan
    Ma, Yulin
    Wang, Guowen
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (11) : 1179 - 1186
  • [7] PIK3CB promotes oesophageal cancer proliferation through the PI3K/AKT/mTOR signalling axis
    Xu, Wei
    Wang, Zhiqiang
    Zhang, Zhi
    Xu, Jian
    Jiang, Yuequan
    CELL BIOLOGY INTERNATIONAL, 2022, 46 (09) : 1399 - 1408
  • [8] Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
    Xuejie Jiang
    Ling Jiang
    Jiaying Cheng
    Fang Chen
    Jinle Ni
    Changxin Yin
    Qiang Wang
    Zhixiang Wang
    Dan Fang
    Zhengshan Yi
    Guopan Yu
    Qingxiu Zhong
    Bing Z. Carter
    Fanyi Meng
    Journal of Translational Medicine, 19
  • [9] Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
    Jiang, Xuejie
    Jiang, Ling
    Cheng, Jiaying
    Chen, Fang
    Ni, Jinle
    Yin, Changxin
    Wang, Qiang
    Wang, Zhixiang
    Fang, Dan
    Yi, Zhengshan
    Yu, Guopan
    Zhong, Qingxiu
    Carter, Bing Z.
    Meng, Fanyi
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [10] Anti-Ischemic Effects of PIK3IP1 Are Mediated through Its Interactions with the ETA-PI3Kγ-AKT Axis
    Park, Jei Hyoung
    Nho, Kyoung Jin
    Lee, Ji Young
    Yoo, Yung Joon
    Park, Woo Jin
    Cho, Chunghee
    Kim, Do Han
    CELLS, 2022, 11 (14)
12345